Cofepris approves 166 new products, including a new molecule to treat Alzheimer’s dementia | Federal Health Risk Prevention Council | Government

  • Biweekly therapeutic expansion report reports authorizations for 28 drugs, 3 clinical trials and 135 medical devices
  • New molecules for the treatment of bacterial conjunctivitis also stand out; stem cell mobilization; postpartum hemorrhage and diarrhea in children over 2 years old and adults

Mexico City, November 10, 2023. – The Federal Council for Protection against Health Risks (Cofepris) announced the latest Bi-Weekly Treatment Extended Report, In the first half of October, authorizations for 166 new hygiene products were communicated through the program.

Of these records, 28 were drug-related, with five new molecules standing out: rivastigmine, an oral solution used for the symptomatic treatment of Alzheimer’s dementia; fusidic acid, used For the topical treatment of bacterial conjunctivitis; Peridotite suspension, for the treatment of diarrhea in children over two years of age and adults; plerixafor, to enhance the mobilization of hematopoietic stem cells into the peripheral blood; and intravenous tranexamic acid, as a treatment for postpartum hemorrhage Auxiliary agents.

Likewise, three new clinical trials were approved, most notably: one designed to evaluate the quality and effectiveness of treatments for large B-cell lymphoma and another designed to treat melanoma.

Clinical trials are studies conducted on humans to find effective and safe hygiene products to diagnose, treat and/or prevent disease.

The report also approved 135 new medical devices, 53 of which were targeted at health care, such as hearing aids, cardiac electrophysiology catheters, embryo transfer and cardiac mapping, and absorbable synthetic bone substitutes.

Within this suite of equipment, 40 new medical devices are expected, such as coagulation analyzers and immune tests as well as surgical medical devices. Likewise, 42 new devices were authorized to diagnose and detect diseases such as hepatitis B and Zika virus.

Creation and publishing Bi-Weekly Treatment Extended Report This is the agency’s transparency initiative for regulated industry and patients, and is a core goal of an agile, equitable and transparent health agency.


Source link

Leave a Comment